Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 23;14(1):16934.
doi: 10.1038/s41598-024-62943-x.

Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study

Tae Woong Seul  1 , Hyun Woo Park  1 , Hyo Yoon Kim  1 , Jung Jin Shin  1 , Sang Wook Son  2
Affiliations

Drug survival analysis of dupilumab and associated predictors in patients with atopic dermatitis in South Korea: single-center, retrospective study

Tae Woong Seul et al. Sci Rep. .

Abstract

Dupilumab is a biologic medication that is used for the treatment of moderate-to-severe atopic dermatitis (AD). Long-term data on dupilumab drug survival in Asia patients with AD are limited. A single-center, retrospective study was performed to assess drug survival between March 2019 and March 2023. Drug survival and associated characteristics were analyzed using Kaplan-Meier survival curves and multivariate Cox regression analysis, respectively. A total of 124 patients with AD (Mean age [standard deviation], 26.0 [8.6] years) with a 4 years-overall dupilumab drug survival rate of 87.9%, were included in this study. Characteristics associated with shorter drug survival were the low eczema area and severity index (EASI) scores at baseline (hazard ratio [HR] 0.84; 95% confidence interval [CI] 0.75-0.94, p-value = 0.003) and non-insurance coverage of dupilumab (HR 11.87; 95% CI 3.28-42.99, p-value = 0.001). This retrospective study demonstrated good overall 4-year dupilumab survival (87.6%) in South Korea. Patients with low baseline EASI scores and those who did not have insurance for dupilumab treatment discontinued the therapy frequently. To the best of our knowledge, this is the first long-term dupilumab drug survival study conducted in Asia with predictors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Adverse effects about dupilumab.
Figure 2
Figure 2
Dupilumab overall drug survival.
Figure 3
Figure 3
Predictors of drug survival for discontinuation (Hazard Ratios) determined by multivariate cox regression analysis. aLow baseline EASI score is in the direction of decreasing drug survival.
See this image and copyright information in PMC

References

    1. Beck, L. A. et al. Dupilumab treatment in adults with moderate to severe atopic dermatitis. N. Engl. J. Med.371, 130–139 (2014). 10.1056/NEJMoa1314768 - DOI - PubMed
    1. de Bruin-Weller, M. et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: A placebo-controlled, randomized phase III clinical trial (Liberty AD CAFE). Br. J. Dermatol.178, 1083–1101 (2018). 10.1111/bjd.16156 - DOI - PubMed
    1. Guttman-Yassky, E. et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J. Allergy Clin. Immunol.143, 155–172 (2019). 10.1016/j.jaci.2018.08.022 - DOI - PubMed
    1. Khosravi, H. et al. Dupilumab drug survival, treatment failures, and insurance approval at a tertiary care center in the United States. J. Am. Acad. Dermatol.82, 1023–1024 (2020). 10.1016/j.jaad.2019.12.034 - DOI - PubMed
    1. Napolitano, M. et al. Drug survival analysis of dupilumab and cyclosporin in patients with atopic dermatitis: A multicenter study. J. Dermatol. Treat.33, 2670–2673 (2022).10.1080/09546634.2022.2067818 - DOI - PubMed

Substances

LinkOut - more resources